GLP-1s are transforming the lives of people with diabetes and obesity by improving blood glucose control and promoting substantial weight loss. However, medication adherence is a significant challenge.

US-based Vivani Medical, a clinical-stage biopharmaceutical company, is developing miniature implants which are designed to solve this problem. Once inserted, patients and caregivers can be confident that the intended medicine is being delivered throughout the once- or twice-yearly dosing interval.

In this episode of BioBiz Buzz, CEO and co-founder Dr. Adam Mendelsohn, discusses the company’s NanoPortal platform technology with your host Shani Alexander. The platform centers on vertically aligned titanium dioxide nanotubes, incredibly tiny, precise channels that are over 40 micrometers in length and attached to a titanium substrate. The key innovation lies in the pore sizing: when the pore is only slightly larger than the drug molecule, the system achieves near-constant, steady-rate medication delivery over many months.

With chronic disease management placing a huge burden on patients - remembering doses, managing side effects and making frequent visits to clinics, the NanoPortal platform is built around a fundamental principle: to maintain steady, consistent drug levels over extended periods, to guarantee adherence and potentially improve tolerability.

Mendelsohn says that the company is reimagining how GLP-1s can be delivered. For him, the NanoPortal platform represents a fundamental shift from treatment management to treatment assurance. The technology could move the healthcare system toward a model where patients receive a simple procedure every few months and know they're getting optimal, consistent therapy, he argues.

Beyond individual patient outcomes, Mendelsohn believes the platform could have massive implications for healthcare economics. Poor medication adherence costs the US healthcare system hundreds of billions of dollars annually. He explains that if patients can get the full benefit of their prescribed therapies, this can lead to both better outcomes and significant cost savings.

● Feedback

● Subscribe (Get notified when new episodes are available. NO marketing!)

● Disclaimer

● LinkedIn